Showing: 1 - 3 of 3 RESULTS

What’s in Store for Edwards Lifesciences’ (EW) Q3 Earnings?

Edwards Lifesciences Corporation EW is slated to report third-quarter 2020 results on Oct 21, after market close.

In the last reported quarter, the company posted an earnings surprise of 126.67%.

Let’s see how things are shaping up prior to this announcement.

Factors at Play

Critical Care

The third-quarter results are expected to reflect a mixed performance by the core Critical Care product group. The pandemic has continued to impact the procedural volumes in the segment, as elective procedures have been deferred. Global demand has been soft due to the pandemic-led business disruptions over the past few months.

However, management is optimistic about the robust customer adoption of the TruWave disposable pressure monitoring devices, despite the challenging pandemic-led market conditions. This is likely to be reflected in the third-quarter results. Robust demand for Edwards Lifesciences’ ICU products is also likely to have boosted the top line.

However, a decline in HemoSphere

Read More

This Big Earnings Beat Means Bed Bath & Beyond Stock Can Run to $40

InvestorPlace – Stock Market News, Stock Advice & Trading Tips

Ever since the Covid-19 pandemic ravished the physical retail sector, I’ve been loudly bullish on Bed Bath & Beyond (NASDAQ:BBBY), calling the depressed retailer one of the best and most overlooked turnaround stories in the entire market. See here, here, here and here. BBBY stock  just proved me right, by reporting blowout second quarter numbers which smashed expectations and largely underscored that the home goods retailer is in the midst of a big comeback.

Stocks to Buy Under $10: Bed Bath & Beyond (<a src=

BBBY stock popped more than 35% on the earnings beat. Shares are now up 494% from their coronavirus lows. This rally isn’t over just yet.

Bed Bath & Beyond stock was so depressed — and so many people on Wall Street thought this company was going bankrupt — that even if the company just stabilizes sales and slightly improves margins over the next few

Read More

Bed Bath & Beyond Stock Soars on Earnings Beat: Will It Last?

After a dismal performance in fiscal 2019, Bed Bath & Beyond (NASDAQ:BBBY) got off to an awful start in fiscal 2020. The COVID-19 pandemic caused sales to plunge 49% in the first quarter, leading to a $243 million adjusted net loss and a $302 million net loss under generally accepted accounting principles (GAAP).

Bed Bath & Beyond made a big comeback in the second quarter, surprising analysts with comparable sales growth and a quarterly profit. Bed Bath & Beyond stock jumped 38% in the two days following the earnings report last week, rallying to a 52-week high. However, investors may be overestimating the company’s turnaround progress. Bed Bath & Beyond is not out of the woods yet.

BBBY Chart

Bed Bath & Beyond stock performance, data by YCharts.

A bounce-back quarter

Bed Bath & Beyond generated decent store traffic in the second quarter, despite the pandemic, with in-store sales down only 18%

Read More